Treatment outcome in patients with triple negative early stage breast cancers compared with other molecular subtypes
Radiation Oncology Journal
;
: 124-131, 2012.
Artículo
en Inglés
| WPRIM
| ID: wpr-97536
ABSTRACT
PURPOSE:
To determine whether triple negative (TN) early stage breast cancers have poorer survival rates compared with other molecular types. MATERIALS ANDMETHODS:
Between August 2000 and July 2006, patients diagnosed with stage I, II early stage breast cancers, in whom all three markers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor [HER]-2) were available and treated with modified radical mastectomy or breast conserving surgery followed by radiotherapy, were retrospectively reviewed.RESULTS:
Of 446 patients, 94 (21.1%) were classified as TN, 57 (12.8%) as HER-2 type, and 295 (66.1%) as luminal. TN was more frequently associated with young patients younger than 35 years old (p = 0.002), higher histologic grade (p 0.05).CONCLUSION:
We found that patients with TN early stage breast cancers had no difference in survival rates compared with other molecular subtypes. Prospective study in homogeneous treatment group will need for a prognosis of TN early stage breast cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fenobarbital
/
Pronóstico
/
Recurrencia
/
Mama
/
Neoplasias de la Mama
/
Mastectomía Radical Modificada
/
Mastectomía Segmentaria
/
Receptores de Progesterona
/
Tasa de Supervivencia
/
Estudios Retrospectivos
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Humanos
Idioma:
Inglés
Revista:
Radiation Oncology Journal
Año:
2012
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS